
New research indicates that psilocybin may help some people quit smoking by producing lasting shifts in perspective, adding momentum to psychedelic-assisted therapy trials. The recent ketamine-plus-buprenorphine study demonstrates a parallel trend: psychoactive medications can produce rapid, clinically meaningful changes in mental states, supporting broader investment in and comparative study of different fast-acting pharmacologic approaches for addiction, suicide prevention, and other psychiatric needs.
Click a connection line between nodes to view confidence and evidence.